Ropinirole, a Non-Ergoline Dopamine Agonist
Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article pr...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Jost, Wolfgang H. [verfasserIn] Angersbach, Dieter [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Publishing Ltd ; 2005 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2006 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: CNS drug reviews - Branford, CT : Neva Press, 1995, 11(2005), 3, Seite 0 |
| Übergeordnetes Werk: |
volume:11 ; year:2005 ; number:3 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1527-3458.2005.tb00046.x |
|---|
| Katalog-ID: |
NLEJ242553281 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242553281 | ||
| 003 | DE-627 | ||
| 005 | 20230505183714.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2005 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1527-3458.2005.tb00046.x |2 doi | |
| 035 | |a (DE-627)NLEJ242553281 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Jost, Wolfgang H. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ropinirole, a Non-Ergoline Dopamine Agonist |
| 264 | 1 | |a Oxford, UK |b Blackwell Publishing Ltd |c 2005 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far.Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome. | ||
| 533 | |d 2006 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2006|||||||||| | ||
| 650 | 4 | |a Dopamine agonists | |
| 700 | 1 | |a Angersbach, Dieter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t CNS drug reviews |d Branford, CT : Neva Press, 1995 |g 11(2005), 3, Seite 0 |h Online-Ressource |w (DE-627)NLEJ24392576X |w (DE-600)2232639-X |x 1527-3458 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2005 |g number:3 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1527-3458.2005.tb00046.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2005 |e 3 |h 0 | ||
| author_variant |
w h j wh whj d a da |
|---|---|
| matchkey_str |
article:15273458:2005----::oiioennroieoa |
| hierarchy_sort_str |
2005 |
| publishDate |
2005 |
| allfields |
10.1111/j.1527-3458.2005.tb00046.x doi (DE-627)NLEJ242553281 DE-627 ger DE-627 rakwb Jost, Wolfgang H. verfasserin aut Ropinirole, a Non-Ergoline Dopamine Agonist Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far.Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Dopamine agonists Angersbach, Dieter verfasserin aut In CNS drug reviews Branford, CT : Neva Press, 1995 11(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ24392576X (DE-600)2232639-X 1527-3458 nnns volume:11 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1527-3458.2005.tb00046.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2005 3 0 |
| spelling |
10.1111/j.1527-3458.2005.tb00046.x doi (DE-627)NLEJ242553281 DE-627 ger DE-627 rakwb Jost, Wolfgang H. verfasserin aut Ropinirole, a Non-Ergoline Dopamine Agonist Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far.Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Dopamine agonists Angersbach, Dieter verfasserin aut In CNS drug reviews Branford, CT : Neva Press, 1995 11(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ24392576X (DE-600)2232639-X 1527-3458 nnns volume:11 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1527-3458.2005.tb00046.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2005 3 0 |
| allfields_unstemmed |
10.1111/j.1527-3458.2005.tb00046.x doi (DE-627)NLEJ242553281 DE-627 ger DE-627 rakwb Jost, Wolfgang H. verfasserin aut Ropinirole, a Non-Ergoline Dopamine Agonist Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far.Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Dopamine agonists Angersbach, Dieter verfasserin aut In CNS drug reviews Branford, CT : Neva Press, 1995 11(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ24392576X (DE-600)2232639-X 1527-3458 nnns volume:11 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1527-3458.2005.tb00046.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2005 3 0 |
| allfieldsGer |
10.1111/j.1527-3458.2005.tb00046.x doi (DE-627)NLEJ242553281 DE-627 ger DE-627 rakwb Jost, Wolfgang H. verfasserin aut Ropinirole, a Non-Ergoline Dopamine Agonist Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far.Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Dopamine agonists Angersbach, Dieter verfasserin aut In CNS drug reviews Branford, CT : Neva Press, 1995 11(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ24392576X (DE-600)2232639-X 1527-3458 nnns volume:11 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1527-3458.2005.tb00046.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2005 3 0 |
| allfieldsSound |
10.1111/j.1527-3458.2005.tb00046.x doi (DE-627)NLEJ242553281 DE-627 ger DE-627 rakwb Jost, Wolfgang H. verfasserin aut Ropinirole, a Non-Ergoline Dopamine Agonist Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far.Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Dopamine agonists Angersbach, Dieter verfasserin aut In CNS drug reviews Branford, CT : Neva Press, 1995 11(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ24392576X (DE-600)2232639-X 1527-3458 nnns volume:11 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1527-3458.2005.tb00046.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2005 3 0 |
| source |
In CNS drug reviews 11(2005), 3, Seite 0 volume:11 year:2005 number:3 pages:0 |
| sourceStr |
In CNS drug reviews 11(2005), 3, Seite 0 volume:11 year:2005 number:3 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Dopamine agonists |
| isfreeaccess_bool |
false |
| container_title |
CNS drug reviews |
| authorswithroles_txt_mv |
Jost, Wolfgang H. @@aut@@ Angersbach, Dieter @@aut@@ |
| publishDateDaySort_date |
2005-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ24392576X |
| id |
NLEJ242553281 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242553281</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505183714.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1527-3458.2005.tb00046.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242553281</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jost, Wolfgang H.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ropinirole, a Non-Ergoline Dopamine Agonist</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far.Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2006</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2006||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dopamine agonists</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Angersbach, Dieter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">CNS drug reviews</subfield><subfield code="d">Branford, CT : Neva Press, 1995</subfield><subfield code="g">11(2005), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ24392576X</subfield><subfield code="w">(DE-600)2232639-X</subfield><subfield code="x">1527-3458</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1527-3458.2005.tb00046.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2005</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Jost, Wolfgang H. |
| spellingShingle |
Jost, Wolfgang H. misc Dopamine agonists Ropinirole, a Non-Ergoline Dopamine Agonist |
| authorStr |
Jost, Wolfgang H. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ24392576X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1527-3458 |
| topic_title |
Ropinirole, a Non-Ergoline Dopamine Agonist Dopamine agonists |
| publisher |
Blackwell Publishing Ltd |
| publisherStr |
Blackwell Publishing Ltd |
| topic |
misc Dopamine agonists |
| topic_unstemmed |
misc Dopamine agonists |
| topic_browse |
misc Dopamine agonists |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
CNS drug reviews |
| hierarchy_parent_id |
NLEJ24392576X |
| hierarchy_top_title |
CNS drug reviews |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ24392576X (DE-600)2232639-X |
| title |
Ropinirole, a Non-Ergoline Dopamine Agonist |
| ctrlnum |
(DE-627)NLEJ242553281 |
| title_full |
Ropinirole, a Non-Ergoline Dopamine Agonist |
| author_sort |
Jost, Wolfgang H. |
| journal |
CNS drug reviews |
| journalStr |
CNS drug reviews |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2005 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Jost, Wolfgang H. Angersbach, Dieter |
| container_volume |
11 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Jost, Wolfgang H. |
| doi_str_mv |
10.1111/j.1527-3458.2005.tb00046.x |
| author2-role |
verfasserin |
| title_sort |
ropinirole, a non-ergoline dopamine agonist |
| title_auth |
Ropinirole, a Non-Ergoline Dopamine Agonist |
| abstract |
Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far.Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome. |
| abstractGer |
Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far.Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome. |
| abstract_unstemmed |
Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far.Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
3 |
| title_short |
Ropinirole, a Non-Ergoline Dopamine Agonist |
| url |
http://dx.doi.org/10.1111/j.1527-3458.2005.tb00046.x |
| remote_bool |
true |
| author2 |
Angersbach, Dieter |
| author2Str |
Angersbach, Dieter |
| ppnlink |
NLEJ24392576X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1111/j.1527-3458.2005.tb00046.x |
| up_date |
2024-07-06T02:22:19.008Z |
| _version_ |
1803794554823901184 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242553281</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505183714.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1527-3458.2005.tb00046.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242553281</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jost, Wolfgang H.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ropinirole, a Non-Ergoline Dopamine Agonist</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far.Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2006</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2006||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dopamine agonists</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Angersbach, Dieter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">CNS drug reviews</subfield><subfield code="d">Branford, CT : Neva Press, 1995</subfield><subfield code="g">11(2005), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ24392576X</subfield><subfield code="w">(DE-600)2232639-X</subfield><subfield code="x">1527-3458</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1527-3458.2005.tb00046.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2005</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.3971157 |